SRSimone Rivolo

Simone Rivolo

*This is an algorithmically generated author record based on publicly available information.

Simone Rivolo has a total of 77 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Transportability of tislelizumab trial outcomes from RATIONALE-315, RATIONALE-303, and RATIONALE-312 to the European population in early-stage non-small cell lung cancer (NSCLC), advanced NSCLC and extensive-stage small cell lung cancer (ES-SCLC)

    by Francesco Passiglia, Eugenia Priedane, Silvy Mardiguian, Mariana Farraia, Anuja Pandey, Pragya Shukla, Caroline von Wilamowitz-Moellendorff, Simone Rivolo, Ariadna Mendoza-Naranjo, Shiangjiin Leaw, et al.

    1. Lung cancer is a global health concern with high incidence and mortality rates. In 2022, it was the most frequently diagnosed cancer, with 2.5 million new cases, representing 12.4% of all cancer...

  • Open Access

    Cost-effectiveness and cost-utility analysis of somatrogon once-weekly injections vs. daily growth hormone injection for treating paediatric growth hormone deficiency in Ireland

    by Simone Rivolo, Jane Loftus, Balazs Peter, Marion Fahey, Thitima Kongnakorn

    Paediatric growth hormone deficiency (pGHD) manifests as growth failure associated with inadequate growth hormone (GH) production. Daily injections of recombinant human GH (dGH) [somatropin] is the current standard of care, which has been shown to be well tolerated and effective, but associated with suboptimal adherence, leading to reduced effectiveness. Somatrogon, a once-weekly injectable long-acting human GH, has demonstrated clinical non-inferiority and significantly lower life interference (i.e. treatment burden) vs. somatropin in two Phase 3 studies. This work evaluated cost-effectiveness and cost-utility of somatrogon vs dGHs from an Irish payer perspective. A Markov model was developed for patients starting somatrogon or dGHs treatment at 3-12 years and continuing up to achievement of near adult height (NAH), with growth driven by trial-based height velocity (HV) and treatment-specific adherence. Patients could discontinue treatment at the end of Year 1 (4%). DGH adherence (95.3%-65% over treatment duration) and adherence-growth relationship were based on published evidence. Higher Year 1 adherence of 4%, tapering over time, for somatrogon vs. dGHs was based on clinical consultation. Treatment costs, monitoring costs and costs due to different wastage types (device setting and adherence) were sourced from local data. Health utilities based on height and injection frequency were derived from published literature. Scenario analysis, deterministic and probabilistic sensitivity analysis were performed. Somatrogon treatment led to 1.87-3.66 cm greater NAH gain and 0.21-0.50 higher quality adjusted life years (QALYs) vs. dGHs, across the base case and scenarios evaluated. Somatrogon treatment was associated with cost savings of €5,699-€21,974 and lower cost per cm gained vs. dGHs (€197-€527), per patient. Somatrogon was cost-effective vs. dGHs, with the result consistent across the sensitivity analyses conducted. Somatrogon weekly injections were estimated to result in higher NAH, higher QALYs, lower overall costs and lower costs per cm gained than dGHs, in pGHD.


  • Open Access

    Cost-effectiveness analysis of apixaban versus vitamin K antagonists for antithrombotic therapy in patients with atrial fibrillation after acute coronary syndrome or percutaneous coronary intervention in Spain

    by Simone Rivolo, Manuela Di Fusco, Carlos Polanco, Amiee Kang, Devender Dhanda, Mirko Savone, Aristeidis Skandamis, Thitima Kongnakorn, Javier Soto

    Background/Objective: AUGUSTUS trial demonstrated that, for patients with atrial fibrillation (AF) having acute coronary syndrome (ACS) or undergoing percutaneous coronary intervention (PCI), an antithrombotic regimen with apixaban and P2Y12 resulted in less bleeding, fewer hospitalizations, and similar ischemic events than regimens including a vitamin K antagonist (VKA), aspirin, or both. This study objective was to evaluate long-term health and economic outcomes and the cost-effectiveness of apixaban over VKA, as a treatment option for patients with AF having ACS/PCI.Methods: A lifetime Markov cohort model was developed comparing apixaban versus VKA across multiple treatment strategies (triple [with P2Y12 + aspirin] or dual [with P2Y12] therapy followed by monotherapy [apixaban or VKA]; triple followed by dual and then monotherapy; dual followed by monotherapy). The model adopted the Spanish healthcare perspective, with a 3-month cycle length and costs and health outcomes discounted at 3%.Results: Treatment with apixaban resulted in total cost savings of €883 and higher life years (LYs) and quality-adjusted LYs (QALYs) per patient than VKA (net difference, LYs: 0.13; QALYs: 0.11). Bleeding and ischemic events (per 100 patients) were lower with apixaban than VKA (net difference, –13.9 and –1.8, respectively). Incremental net monetary benefit for apixaban was €3,041, using a willingness-to-pay threshold of €20,000 per QALY. In probabilistic sensitivity analysis, apixaban was dominant in the majority of simulations (92.6%), providing additional QALYs at lower costs than VKA.Conclusions: Apixaban was a dominant treatment strategy than VKA from both the Spanish payer’s and societal perspectives, regardless of treatment strategy considered.


  • Effect of Percutaneous Left Ventricular Unloading on Coronary Flow and Cardiac Coronary Coupling in Patients Undergoing High-Risk Percutaneous Coronary Intervention

    by Natalia Briceno, Matthew Ryan, Kevin O’gAllagher, Tiffany Patterson, Simone Rivolo, Jack Lee, Peter O’kAne, Simon R. Redwood, Ajay M. Shah, Divaka Perera


  • Open Access

    Impact of coronary bifurcation morphology on wave propagation

    by Simone Rivolo, Lucas Hadjilucas, Matthew Sinclair, Pepijn van Horssen, Jeroen van Den Wijngaard, Roman Wesolowski, Amedeo Chiribiri, Maria Siebes, Nicolas P. Smith, Jack Lee

    The branching pattern of the coronary vasculature is a key determinant of its function and plays a crucial role in shaping the pressure and velocity wave forms measured for clinical diagnosis. However, although multiple scaling laws have been proposed to characterize the branching pattern, the implications they have on wave propagation remain unassessed to date. To bridge this gap, we have developed a new theoretical framework by combining the mathematical formulation of scaling laws with the wave propagation theory in the pulsatile flow regime. This framework was then validated in multiple species using high-resolution cryomicrotome images of porcine, canine, and human coronary networks. Results demonstrate that the forward well-matchedness (no reflection for pressure/flow waves traveling from the coronary stem toward the microcirculation) is a salient feature in the coronary vasculature, and this result remains robust under many scenarios of the underlying pulse wave speed distribution assumed in the network. This result also implies a significant damping of the backward traveling waves, especially for smaller vessels (radius, <0.3 mm). Furthermore, the theoretical prediction of increasing area ratios (ratio between the area of the mother and daughter vessels) in more symmetric bifurcations found in the distal circulation was confirmed by experimental measurements. No differences were observed by clustering the vessel segments in terms of transmurality (from epicardium to endocardium) or perfusion territories (left anterior descending, left circumflex, and right coronary artery).


  • Open Access

    Accurate and Standardized Coronary Wave Intensity Analysis

    by Simone Rivolo, Tiffany Patterson, Kaleab N. Asrress, Michael Marber, Simon Redwood, Nicolas P. Smith, Jack Lee

    Objective: Coronary wave intensity analysis (cWIA) has increasingly been applied in the clinical research setting to distinguish between the proximal and distal mechanical influences on coronary blood flow. Recently, a cWIA-derived clinical index demonstrated prognostic value in predicting functional recovery postmyocardial infarction. Nevertheless, the known operator dependence of the cWIA metrics currently hampers its routine application in clinical practice. Specifically, it was recently demonstrated that the cWIA metrics are highly dependent on the chosen Savitzky-Golay filter parameters used to smooth the acquired traces. Therefore, a novel method to make cWIA standardized and automatic was proposed and evaluated in vivo. Methods: The novel approach combines an adaptive Savitzky-Golay filter with high-order central finite differencing after ensemble-averaging the acquired waveforms. Its accuracy was assessed using in vivo human data. The proposed approach was then modified to automatically perform beat wise cWIA. Finally, the feasibility (accuracy and robustness) of the method was evaluated. Results: The automatic cWIA algorithm provided satisfactory accuracy under a wide range of noise scenarios (≤10% and ≤20% error in the estimation of wave areas and peaks, respectively). These results were confirmed when beat-by-beat cWIA was performed. Conclusion: An accurate, standardized, and automated cWIA was developed. Moreover, the feasibility of beat wise cWIA was demonstrated for the first time. Significance: The proposed algorithm provides practitioners with a standardized technique that could broaden the application of cWIA in the clinical practice as enabling multicenter trials. Furthermore, the demonstrated potential of beatwise cWIA opens the possibility investigating the coronary physiology in real time.


  • Open Access

    94 Flow-Contraction Matching in The Human Heart: A Novel Invasive Study of The Complex Cardiac-Coronary Interaction in Ischaemic Heart Disease

    by Tiffany Patterson, Simone Rivolo, Satpal Arri, Brian Clapp, Divaka Perera, Michael Marber, Jack Lee, Simon Redwood

    Background A first-in-human study of simultaneous invasive real-time left ventricular (LV) and coronary haemodynamics in the cardiac catheter lab enabling accurate delineation of the complex cardiac-coronary interaction and influence of antianginal therapy in coronary artery disease (CAD). Method 15 patients completed the protocol (Figure;A&B). Coronary measurements (baseline and 1 mg isosorbide dinitrate, ISDN) were performed with dual sensor pressure-flow wire (ComboWire®) advanced down coronary artery (C) and were electronically routed into the intracardiac analyser (CD Leycom, Netherlands) via which LV haemodynamics – using pressure-volume (PV) loop catheter in LV apex – were measured, thus enabling simultaneous recordings. Coronary blood flow (CBF), wave intensity analysis and LV pressure volume loops were analysed with specially developed in-house software (MatLab R2014b) (E); (paired t-test; linear regression). A. Flouroscopic image of PV loop in the catheter in the LV with combowire in the coronary artery; B. Externalisation of guide catheter with PV loop and pressure-flow wire; C. Coronary flow data obtained on the Combomap console (Volcano Corp); D. LV PV loop at rest (blue) and following administration of nitrates (red) with a reduction in cardiac work; E. In-house softwere developed on MatLab R2014b – snapshot delineating LEFT coronary blood flow, MIDDLE. LV (black), aortic (red) and distal coronary pressure (blue) and RIGHT PV loop. F. Left upper and depicting distal coronary pressure and flow, left middle: LV pressure and volume plotted against time and left lower: wave intensity analysis, right middle forward going waves in coronary circulation depicted in relation to cardiac contraction, right lower: backward travelling (suction) waves in relation to cardiac cycle Results Accurate delineation and timings of the backward and forward waves were described relative to cardiac contraction and relaxation (F). Backward expansion wave (BEW) occurred during isovolumic relaxation and correlated for the first time with peak dpdt- (r20.4 p = 0.0015) and found to be load dependent (F); forward compression wave (FCW) occurred immediately following peak dpdt+; ISDN drove leftward, downward shift of PV loop (D) accompanied by two-step cardiovascular response 1) significant afterload reduction (endsystolic pressure 127+/-±23;98±22 mmHg; p < 0.01) associated with reduction in cardiac work (pressure volume area 1.4±0.4;1.1±0.4J) total peripheral resistance and arterial elastance representing systemic vasodilation and significant improvement in mechanical efficiency (68 to 74%) 2) Reduction in preload (14±5;10±5 mmHg; p < 0.01) was associated with improved passive (EDPVR B) and active (Tau) diastolic relaxation (38±4;36±4 ms; p < 0.01). Despite a reduction in perfusion pressure, coronary flow was maintained. Conclusion For the first time in humans we relate coronary flow to cardiac contraction-relaxation and describe how ISDN exerts an anti-anginal effect by reduction in afterload and preload, therefore cardiac work and improved cardiac efficiency, maintaining coronary flow despite reduction in perfusion pressure, thus vastly increasing our understanding of the integrated cardiovascular response.

  • Open Access

    In silico coronary wave intensity analysis: application of an integrated one-dimensional and poromechanical model of cardiac perfusion

    by Jack Lee, David Nordsletten, Andrew Cookson, Simone Rivolo, Nicolas Smith

    Coronary wave intensity analysis (cWIA) is a diagnostic technique based on invasive measurement of coronary pressure and velocity waveforms. The theory of WIA allows the forward- and backward-propagating coronary waves to be separated and attributed to their origin and timing, thus serving as a sensitive and specific cardiac functional indicator. In recent years, an increasing number of clinical studies have begun to establish associations between changes in specific waves and various diseases of myocardium and perfusion. These studies are, however, currently confined to a trial-and-error approach and are subject to technological limitations which may confound accurate interpretations. In this work, we have developed a biophysically based cardiac perfusion model which incorporates full ventricular–aortic–coronary coupling. This was achieved by integrating our previous work on one-dimensional modelling of vascular flow and poroelastic perfusion within an active myocardial mechanics framework. Extensive parameterisation was performed, yielding a close agreement with physiological levels of global coronary and myocardial function as well as experimentally observed cumulative wave intensity magnitudes. Results indicate a strong dependence of the backward suction wave on QRS duration and vascular resistance, the forward pushing wave on the rate of myocyte tension development, and the late forward pushing wave on the aortic valve dynamics. These findings are not only consistent with experimental observations, but offer a greater specificity to the wave-originating mechanisms, thus demonstrating the value of the integrated model as a tool for clinical investigation.